source
- Xaira Therapeutics details its generative AI antibody platform X-Design and unveils first pipeline candidatesXaira Therapeutics, which raised $1 billion in 2024, has now shared details of its AI-driven antibody design platform called X-Design and provided a glimpse of its emerging pipeline. The company s…
- Novartis pays $575 million upfront for worldwide rights to Abogen’s CD19xCD3 mRNA T-cell engagerNovartis announced it will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to its lead early‑stage CD19xCD3 mRNA T‑cell engager. The agreement gives Novartis access to t…